ASX Announcement September 2026 Quarterly Activities Report & Appendix 4C ? First patient safely treated with RC220 & osimertinib in the HARNESS-1 trial for patients with EGFR-mutated non-small cell lung cancer ? Phase 1 CPACS trial expands to South Korea, allowing for accelerated patient...